HomeCompareFTEKX vs MRK

FTEKX vs MRK: Dividend Comparison 2026

FTEKX yields 14.70% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FTEKX wins by $21.7K in total portfolio value
10 years
FTEKX
FTEKX
● Live price
14.70%
Share price
$13.61
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.4K
Annual income
$3,645.55
Full FTEKX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — FTEKX vs MRK

📍 FTEKX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFTEKXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FTEKX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FTEKX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FTEKX
Annual income on $10K today (after 15% tax)
$1,249.08/yr
After 10yr DRIP, annual income (after tax)
$3,098.72/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, FTEKX beats the other by $2,290.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FTEKX + MRK for your $10,000?

FTEKX: 50%MRK: 50%
100% MRK50/50100% FTEKX
Portfolio after 10yr
$41.6K
Annual income
$2,297.93/yr
Blended yield
5.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FTEKX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FTEKX buys
0
MRK buys
0
No recent congressional trades found for FTEKX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFTEKXMRK
Forward yield14.70%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$52.4K$30.7K
Annual income after 10y$3,645.55$950.29
Total dividends collected$25.1K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FTEKX vs MRK ($10,000, DRIP)

YearFTEKX PortfolioFTEKX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,170$1,469.51$11,192$351.54+$978.00FTEKX
2$14,693$1,671.33$12,524$392.70+$2.2KFTEKX
3$17,607$1,885.84$14,015$438.65+$3.6KFTEKX
4$20,952$2,112.06$15,682$489.96+$5.3KFTEKX
5$24,767$2,348.84$17,547$547.23+$7.2KFTEKX
6$29,096$2,594.94$19,632$611.16+$9.5KFTEKX
7$33,981$2,849.03$21,963$682.53+$12.0KFTEKX
8$39,470$3,109.76$24,571$762.18+$14.9KFTEKX
9$45,608$3,375.73$27,486$851.08+$18.1KFTEKX
10$52,447$3,645.55$30,745$950.29+$21.7KFTEKX

FTEKX vs MRK: Complete Analysis 2026

FTEKXStock

The investment seeks long-term growth of capital. Normally the fund invests at least 80% of assets in securities of disruptive technology companies. Normally it invests primarily in equity securities. Companies within the disruptive technology theme include but are not limited to those companies that, in the Adviser&#39;s opinion, are engaged in big data, machine learning, artificial intelligence, cloud computing/software as a service (SaaS), cybersecurity, ecommerce and consumer technologies, rideshare, and next generation hardware. In pursuing this investment theme, the fund may invest in companies in any economic sector. The fund is non-diversified.

Full FTEKX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this FTEKX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FTEKX vs SCHDFTEKX vs JEPIFTEKX vs OFTEKX vs KOFTEKX vs MAINFTEKX vs JNJFTEKX vs ABBVFTEKX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.